Jinfeng Lou

Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials

Xiaojiao Li, Yusi Liu, Meng Wang et al. · The Lancet Infectious Diseases · 2024 · 17 citations

Medicine, Pharmacokinetics, Pharmacology +13

Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment

Yue Hu, Xiaojiao Li, Jingrui Liu et al. · Annals of Medicine · 2022 · 16 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial

Yue Hu, Haijun Li, Hong Zhang et al. · Nature Communications · 2023 · 16 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7

Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial

Xiaojiao Li, Yusi Liu, Hanxin Yao et al. · Antimicrobial Agents and Chemotherapy · 2022 · 13 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +8

Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virus

Hong Zhang, Xiaoxue Zhu, Qingmei Li et al. · Journal of Pharmacy and Pharmacology · 2018 · 11 citations

Medicine, Pharmacokinetics, Pharmacology +15